Benitec Biopharma Inc. (BNTC)

Benitec Biopharma Income Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Operating Revenue	-	-	-	0.08	0.07	0.06
Revenue	-	-	-	0.08	0.07	0.06
Revenue Growth (YoY)	-	-	-	2.74%	23.73%	-42.16%
Cost of Revenue	-	-	-0.11	-	0.01	0.12
Gross Profit	-	-	0.11	0.08	0.06	-0.06
Selling, General & Admin	27.66	23.43	6.99	6.38	6.65	6.51
Research & Development	18.12	18.33	15.61	12.77	11.27	7.02
Operating Expenses	45.78	41.77	22.6	19.16	17.92	13.53
Operating Income	-45.78	-41.77	-22.49	-19.08	-17.85	-13.6
Interest Expense	-	-	-	-0.03	-0.03	-0.01
Interest & Investment Income	3.69	3.29	0.9	-	-	-
Currency Exchange Gain (Loss)	-0.25	-0.07	0.04	-0.42	-0.23	-0.33
Other Non Operating Income (Expenses)	-0.25	-0.13	-0.2	-0.03	-0.08	-
EBT Excluding Unusual Items	-42.59	-38.68	-21.75	-19.56	-18.2	-13.94
Gain (Loss) on Sale of Investments	-	-	-0	-0	-0.01	0.02
Other Unusual Items	0.76	0.76	-	-	-	0.04
Pretax Income	-41.82	-37.92	-21.75	-19.56	-18.21	-13.88
Net Income	-41.82	-37.92	-21.75	-19.56	-18.21	-13.88
Preferred Dividends & Other Adjustments	-	-	0.62	-	-	-
Net Income to Common	-41.82	-37.92	-22.37	-19.56	-18.21	-13.88
Shares Outstanding (Basic)	40	36	18	1	0	0
Shares Outstanding (Diluted)	40	36	18	1	0	0
Shares Change (YoY)	59.78%	97.17%	1225.17%	188.30%	90.24%	320.63%
EPS (Basic)	-1.06	-1.05	-1.22	-14.12	-37.88	-54.94
EPS (Diluted)	-1.06	-1.05	-1.22	-14.12	-37.88	-54.94
Free Cash Flow	-22.37	-23.61	-19.58	-18.01	-15.91	-13.05
Free Cash Flow Per Share	-0.56	-0.65	-1.07	-13.00	-33.10	-51.66
Gross Margin	-	-	-	100.00%	87.67%	-108.47%
Operating Margin	-	-	-	-25441.33%	-24457.53%	-23044.07%
Profit Margin	-	-	-	-26082.67%	-24942.47%	-23528.81%
Free Cash Flow Margin	-	-	-	-24017.33%	-21797.26%	-22123.73%
EBITDA	-45.72	-41.7	-22.4	-18.95	-17.69	-13.37
D&A For EBITDA	0.05	0.07	0.09	0.14	0.17	0.23
EBIT	-45.78	-41.77	-22.49	-19.08	-17.85	-13.6

Updated Nov 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q